Ipca Laboratories Ltd.

BSE: IPCALAB524494ISIN INE571A01038

Healthcare
Pharmaceuticals
BSE 500

Share price

₹1,973.15+24.80 (+1.27%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹2,039.30
52W low: ₹1,278.00
Off 52W high: -3.24%
1M return: +1.12%
3M return: +11.68%
6M return: +26.18%
1Y return: +52.33%
20D avg volume: 32,186
50 DMA: ₹1,944.62
200 DMA: ₹1,682.34

Key ratios Consolidated

Market cap: ₹50,051 Cr
Current price: ₹1,973.15
52W high / low: ₹2,039.30 / ₹1,278.00
Face value: ₹1.00
P/E: 36.40
P/B: 6.21
EPS (TTM): ₹54.20
Book value / share: ₹317.85
ROE: —
ROCE: 16.40%
Operating margin: —
Net margin: —
Debt / equity: 0.07
Net debt: ₹266.82 Cr
Interest cover: 21.71
Dividend yield: 0.30%
Dividend / share (TTM): ₹6.00
Payout: 11.07%
Cash conversion cycle: 143.9 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	2,788	2,388	2,392	2,556	2,309	2,247	2,245	2,355	2,093	2,033	2,053	2,034
	25.26	93.74	20.19	27.86	32.66	25.82	20.11	26.26	20.61	18.92	22.45	38.55
	2,813	2,482	2,413	2,584	2,342	2,273	2,265	2,381	2,113	2,052	2,075	2,073
	2,241	2,032	1,984	2,135	2,011	1,939	1,898	2,036	1,823	1,839	1,854	1,847
	638.14	592.60	564.44	569.87	617.10	660.07	482.44	588.99	545.32	565.05	609.95	608.90
	140.69	149.22	129.83	126.83	126.74	86.98	188.29	153.83	118.68	108.57	116.32	144.09
	601.56	533.00	546.09	537.94	543.17	500.84	485.44	509.84	487.87	466.01	459.04	425.87
	11.88	20.20	17.62	19.61	18.51	21.51	16.81	22.56	24.05	29.37	33.40	44.12
	110.81	107.14	107.59	103.33	100.06	100.12	98.46	100.35	98.89	98.13	99.50	90.34
	719.68	679.99	655.16	692.00	657.70	608.70	628.64	—	568.55	559.21	565.54	609.24
	572.08	450.27	428.33	449.84	330.51	333.05	367.92	344.83	290.39	213.32	220.88	225.36
	0.00	-45.82	17.65	-58.26	0.00	-205.05	0.00	0.00	0.00	-136.72	68.01	0.00
	572.08	404.45	445.98	391.58	330.51	128.00	367.92	344.83	290.39	76.60	288.89	225.36
	149.27	95.05	81.93	108.08	96.09	62.22	90.59	99.39	91.41	73.69	66.24	87.92
	424.27	306.69	363.67	280.53	232.89	63.99	276.36	245.75	199.14	1.33	221.00	136.49
	15.84	11.79	12.86	11.14	9.19	2.67	9.78	9.05	7.58	2.35	7.09	5.72
Key metrics
	694.77	531.79	571.19	514.52	449.08	249.63	483.19	467.74	413.33	204.10	421.79	359.82
	24.90%	22.30%	23.90%	20.10%	19.50%	11.10%	21.50%	19.90%	19.80%	10.00%	20.50%	17.70%
	15.20%	12.80%	15.20%	11.00%	10.10%	2.80%	12.30%	10.40%	9.50%	0.10%	10.80%	6.70%
	—	4.20%	—	4.20%	—	1.60%	—	—	—	—	—	—
	20.80%	6.30%	6.60%	8.60%	10.30%	10.50%	9.40%	15.80%	—	—	—	—
	82.20%	379.30%	31.60%	14.20%	16.90%	4,711.30%	25.00%	80.00%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Income statement
	10,126	9,646	8,940	7,705	6,244	5,830	5,420	4,649	3,773	3,284	3,211
	167.05	174.45	92.80	124.77	125.62	66.57	62.84	67.00	57.68	41.80	22.57
	10,293	9,821	9,032	7,830	6,370	5,896	5,483	4,716	3,831	3,325	3,233
	8,392	8,162	7,696	6,879	5,625	4,761	4,094	3,969	3,283	3,035	2,963
	2,365	2,344	2,277	2,216	1,709	1,664	1,597	1,460	1,106	932.37	953.87
	546.57	532.62	547.78	490.07	497.19	480.30	325.95	359.88	249.07	168.91	—
	2,219	2,160	1,984	1,708	1,288	1,177	1,014	921.23	787.40	735.88	—
	69.31	75.94	84.93	138.27	45.54	7.69	9.04	16.50	18.87	24.02	24.08
	428.87	418.12	397.82	357.24	261.56	232.42	209.17	210.50	182.42	—	—
	2,747	2,685	2,451	2,100	1,723	—	1,134	1,177	—	968.19	959.69
	1,901	1,659	1,336	950.42	745.29	1,136	1,389	746.70	548.27	290.53	270.32
	-86.43	-86.43	-205.05	-107.75	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	1,814	1,573	1,131	842.67	745.29	1,136	1,389	746.70	548.27	290.53	270.32
	434.33	381.15	343.61	313.46	253.36	224.27	240.14	135.33	104.24	51.11	67.52
	1,375	1,184	785.24	522.92	478.99	889.79	1,141	603.56	442.22	239.42	194.54
	51.63	44.98	29.08	21.57	18.58	34.85	90.11	47.77	35.01	—	—
Key metrics
	2,312	2,067	1,614	1,338	1,052	1,376	1,607	973.70	749.56	314.55	294.40
	22.84%	21.40%	18.10%	17.40%	16.90%	23.60%	29.70%	20.90%	19.90%	9.60%	9.20%
	13.58%	12.30%	8.80%	6.80%	7.70%	15.30%	21.10%	13.00%	11.70%	7.30%	6.10%
	—	16.40%	13.00%	—	—	—	—	—	—	—	—
	10.59%	7.90%	16.00%	23.40%	7.10%	7.60%	16.60%	23.20%	14.90%	2.30%	—
	67.91%	50.80%	50.20%	9.20%	-46.20%	-22.00%	89.10%	36.50%	84.70%	23.10%	—
	—	489.71	545.80	—	—	—	—	—	—	—	—
	—	0.96	1.68	—	—	—	—	—	—	—	—
	—	0.07	0.16	—	—	—	—	—	—	—	—
	—	266.82	1,135	—	—	—	—	—	—	—	—
	—	143.9	146.5	—	—	—	—	—	—	—	—
Balance sheet
	—	12,370	11,761	—	—	—	—	—	—	—	—
	—	6,374	5,967	—	—	—	—	—	—	—	—
	—	437.12	167.17	—	—	—	—	—	—	—	—
	—	2,014	1,874	—	—	—	—	—	—	—	—
	—	2,731	2,560	—	—	—	—	—	—	—	—
	—	362.82	343.92	—	—	—	—	—	—	—	—
	—	4,441	4,069	—	—	—	—	—	—	—	—
	—	940.29	846.17	—	—	—	—	—	—	—	—
	—	2,307	2,384	—	—	—	—	—	—	—	—
	—	703.94	1,302	—	—	—	—	—	—	—	—
	—	594.82	758.46	—	—	—	—	—	—	—	—
	—	109.12	543.24	—	—	—	—	—	—	—	—
	—	9,524	8,388	—	—	—	—	—	—	—	—
Cash flow
	—	1,142	1,321	—	—	—	—	—	—	—	—
	—	-246.77	-869.50	—	—	—	—	—	—	—	—
	—	-753.53	-282.98	—	—	—	—	—	—	—	—
	—	652.26	775.52	—	—	—	—	—	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	2,119	1,814	1,845	1,930	1,747	1,638	1,663	1,811	1,566	1,511	1,507	1,663
	17.42	29.88	17.82	21.92	25.02	21.49	17.41	17.00	15.39	15.10	16.89	36.14
	2,137	1,844	1,863	1,952	1,772	1,660	1,680	1,828	1,581	1,526	1,524	1,699
	1,621	1,464	1,446	1,544	1,415	1,361	1,325	1,489	1,293	1,304	1,324	1,454
	445.76	406.27	389.15	377.32	395.59	351.67	352.01	378.93	335.03	363.37	411.25	485.72
	110.75	85.03	89.97	89.40	84.11	79.06	81.08	94.76	92.34	78.14	75.25	100.13
	467.32	413.53	421.07	411.39	409.91	377.12	358.48	382.44	361.30	333.22	334.33	336.15
	5.04	10.48	9.51	11.46	12.06	16.20	10.17	17.25	19.42	24.06	27.21	38.64
	74.61	70.31	68.57	66.86	63.13	65.19	62.81	62.65	61.32	61.76	63.02	61.35
	533.87	513.85	504.18	543.57	482.18	457.21	433.85	490.45	398.73	—	413.62	482.65
	515.41	380.27	417.22	408.31	356.75	298.69	355.52	339.21	287.89	221.62	200.15	245.13
	0.00	-30.42	0.00	0.00	0.00	-281.54	—	—	—	-94.32	—	—
	515.41	349.85	417.22	408.31	356.75	17.15	355.52	339.21	287.89	127.30	200.15	245.13
	142.12	87.56	113.77	103.57	94.71	82.20	87.96	95.09	83.76	62.54	63.21	83.00
	373.29	262.29	303.45	304.74	262.04	-65.05	267.56	244.12	204.13	64.76	136.94	162.13
	14.71	10.34	11.96	12.01	10.33	-2.56	10.55	9.62	8.05	2.55	5.40	6.39
Key metrics
	595.06	430.64	495.30	486.63	431.94	98.54	428.50	419.11	368.63	213.12	290.38	345.12
	28.10%	23.70%	26.80%	25.20%	24.70%	6.00%	25.80%	23.10%	23.50%	14.10%	19.30%	20.80%
	17.60%	14.50%	16.40%	15.80%	15.00%	-4.00%	16.10%	13.50%	13.00%	4.30%	9.10%	9.80%
	—	4.30%	—	5.20%	—	0.40%	—	—	—	—	—	—
	21.30%	10.70%	11.00%	6.60%	11.60%	8.50%	10.30%	8.90%	—	—	—	—
	42.50%	503.20%	13.40%	24.80%	28.40%	-200.40%	95.40%	50.60%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17
Income statement
	7,709	7,337	6,678	6,166	5,815	5,399	5,139	4,367	3,633	3,219	3,157
	87.04	94.64	71.29	111.29	111.19	56.13	62.24	64.69	54.59	39.54	22.21
	7,796	7,431	6,749	6,278	5,926	5,455	5,201	4,432	3,688	3,259	3,179
	6,075	5,869	5,468	5,322	5,175	4,367	3,821	3,647	3,130	2,976	2,921
	1,618	1,568	1,418	1,688	1,684	1,601	1,556	1,431	1,098	923.20	947.31
	375.15	348.51	347.24	345.21	280.91	282.90	197.68	204.65	167.87	168.30	—
	1,713	1,656	1,479	1,336	1,193	1,090	948.84	870.79	752.24	712.78	—
	36.49	43.51	63.04	120.67	43.92	7.21	8.14	15.79	18.49	24.02	23.34
	280.35	268.87	251.97	246.48	228.63	204.10	187.72	178.69	171.88	174.36	171.00
	2,095	2,044	1,780	—	1,640	1,303	1,094	1,101	—	952.31	943.98
	1,721	1,563	1,281	955.52	750.49	1,088	1,380	784.97	557.39	282.80	258.20
	-30.42	-30.42	-281.54	-133.36	—	—	—	—	—	—	—
	1,691	1,532	999.77	822.16	750.49	1,088	1,380	784.97	557.39	282.80	258.20
	447.02	399.61	349.01	291.75	244.79	217.42	239.19	132.51	102.48	49.69	69.91
	1,244	1,133	650.76	530.41	505.70	870.94	1,141	652.46	454.91	233.11	188.29
	49.02	44.64	25.65	20.91	19.39	34.33	90.08	51.64	36.01	—	—
Key metrics
	2,008	1,845	1,315	1,189	1,023	1,300	1,576	979.45	747.76	481.18	452.54
	26.04%	25.10%	19.70%	19.30%	17.60%	24.10%	30.70%	22.40%	20.60%	14.90%	14.30%
	16.13%	15.40%	9.70%	8.60%	8.70%	16.10%	22.20%	14.90%	12.50%	7.20%	6.00%
	—	18.90%	13.90%	—	—	—	—	—	—	—	—
	12.39%	9.90%	8.30%	6.10%	7.70%	5.10%	17.70%	20.20%	12.90%	2.00%	—
	75.51%	74.00%	22.70%	4.90%	-41.90%	-23.70%	74.80%	43.40%	95.10%	23.80%	—
	—	712.67	771.47	—	—	—	—	—	—	—	—
	—	1.22	2.11	—	—	—	—	—	—	—	—
	—	0.03	0.13	—	—	—	—	—	—	—	—
	—	-76.35	794.96	—	—	—	—	—	—	—	—
	—	118.1	121.1	—	—	—	—	—	—	—	—
Balance sheet
	—	9,776	9,071	—	—	—	—	—	—	—	—
	—	3,995	3,780	—	—	—	—	—	—	—	—
	—	311.51	76.77	—	—	—	—	—	—	—	—
	—	1,272	1,155	—	—	—	—	—	—	—	—
	—	1,708	1,542	—	—	—	—	—	—	—	—
	—	251.69	193.00	—	—	—	—	—	—	—	—
	—	2,935	2,503	—	—	—	—	—	—	—	—
	—	605.55	481.53	—	—	—	—	—	—	—	—
	—	1,419	1,418	—	—	—	—	—	—	—	—
	—	235.16	871.73	—	—	—	—	—	—	—	—
	—	165.16	389.30	—	—	—	—	—	—	—	—
	—	70.00	482.43	—	—	—	—	—	—	—	—
	—	7,979	6,892	—	—	—	—	—	—	—	—
Cash flow
	—	1,378	1,374	—	—	—	—	—	—	—	—
	—	-696.99	-738.81	—	—	—	—	—	—	—	—
	—	-745.21	-428.44	—	—	—	—	—	—	—	—
	—	665.45	602.60	—	—	—	—	—	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +8.06%
Sales CAGR 5Y: +7.38%
Profit CAGR 3Y: +30.83%
Profit CAGR 5Y: -0.15%
Sales YoY (TTM): +12.39%
Profit YoY (TTM): +75.51%

Consolidated

Sales CAGR 3Y: +15.60%
Sales CAGR 5Y: +12.22%
Profit CAGR 3Y: +35.20%
Profit CAGR 5Y: +0.74%
Sales YoY (TTM): +10.59%
Profit YoY (TTM): +67.91%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 44.72%

Quarter	September 2026	June 2026
Promoter %	44.72%	44.72%

Holder	Type	Holding	Previous	Change
Kaygee Investments Private Limited	Promoter Group	25.49%	25.49%	0.00%
HDFC MUTUAL FUND	Public	9.51%	9.54%	-0.03%
Kaygee Laboratories Private Limited	Promoter Group	6.61%	6.61%	0.00%
KOTAK MAHINDRA MUTUAL FUND	Public	6.34%	6.36%	-0.02%
Chandurkar Investments Private Limited	Promoter Group	5.50%	5.50%	0.00%
DSP MUTUAL FUND	Public	4.12%	4.64%	-0.52%
SBI LIFE INSURANCE CO. LTD	Public	3.53%	3.69%	-0.16%
NIPPON INDIA MUTUAL FUND	Public	2.72%	2.79%	-0.07%
Premchand Godha	Promoter	2.29%	2.29%	0.00%
AXIS MUTUAL FUND	Public	2.04%	1.94%	+0.10%
Usha M Chandurkar	Promoter Group	1.70%	1.70%	0.00%
EDELWEISS TRUSTEESHIP CO LTD	Public	1.21%	—	—
HSBC MUTUAL FUND	Public	1.13%	1.05%	+0.08%
KOTAK MUTUAL FUNDS	Public	1.08%	—	—
HDFC LIFE INSURANCE COMPANY LIMITED	Public	1.07%	1.39%	-0.32%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%

Filings & corporate actions

Recent announcements

Schedule of Conference Call28 Oct 2026 · Company Update / Analyst / Investor Meet
Ipca Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve Standalone and Consolidated ....22 Oct 2026 · Board Meeting / Board Meeting
The Company has enclosed herewith certificate recived from RTA under reg 74 5 for the quarter ended 30.09.2026.12 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Closure of Trading Window22 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Transcript of Conference Call17 Aug 2026 · Company Update / Analyst / Investor Meet
Audiolink for Conference Call held on 14.08.202614 Aug 2026 · Company Update / Analyst / Investor Meet
Copy of Newspaper Publication14 Aug 2026 · Company Update / Newspaper Publication
76th AGM - Voting Results and Scrutinizer Report14 Aug 2026 · AGM/EGM / AGM
Proceedings of AGM13 Aug 2026 · AGM/EGM / AGM
Standalone and Consolidated Unaudited Financial Results for Q1FY2713 Aug 2026 · Result / Financial Results
Standalone and Consolidated Unaudited Financial Results for Q1FY2713 Aug 2026 · Board Meeting / Outcome of Board Meeting
Conference Call to discuss Q1FY27 Results6 Aug 2026 · Company Update / Analyst / Investor Meet
Ipca Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve Standalone and Consolidated ....28 Jul 2026 · Board Meeting / Board Meeting
Intimation of web link to non-email cases17 Jul 2026 · Company Update / General
Copy of Newspaper Publication15 Jul 2026 · Company Update / Newspaper Publication
Record Date for Dividend14 Jul 2026 · Corp. Action / Record Date
76th Annual General Meeting of Ipca Laboratories Limited to be held on Thursday, 13th August, 202614 Jul 2026 · AGM/EGM / AGM
Business Responsibility and Sustainability Reporting (BRSR)14 Jul 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Annual Report 2025-2614 Jul 2026 · Others / Reg. 34 (1) Annual Report
The Company enclosed herewith certificate recived from RTA under reg 74 (5) D P Regulations for the quarter ended 30.06.2026.13 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Credit Rating7 Jul 2026 · Company Update / Credit Rating
Copy of Newspaper Publication2 Jul 2026 · Company Update / Newspaper Publication
Outcome of Board Meeting26 Jun 2026 · Company Update / Scheme of Arrangement
Outcome of Board Meeting26 Jun 2026 · Others / Outcome without intimation
Closure of Trading Window22 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Press Release12 Jun 2026 · Company Update / Press Release / Media Release
Eclsoed copy of newspapers9 Jun 2026 · Company Update / Newspaper Publication
Transcript of Conference Call held on 1st June 20264 Jun 2026 · Company Update / Analyst / Investor Meet
Audio Link of the Conference Call held on 01.06.20261 Jun 2026 · Company Update / Analyst / Investor Meet
Copy of Newspaper publications1 Jun 2026 · Company Update / Newspaper Publication
Revised Link for Q4FY26 Conference Call to be held today1 Jun 2026 · Company Update / General
Recommendation of Dividend29 May 2026 · Corp Action / Dividend Updates
Re-appointment of Mr. Prashant Godha, as Executive Director29 May 2026 · Company Update / Change in Management
Standalone and Consolidated Results Q4FY2629 May 2026 · Result / Financial Results
Outcome of Board Meeting29 May 2026 · Board Meeting / Outcome of Board Meeting
The Company has encloseing herewith Annual Secretarial Companice Report for the FY 2025-26.27 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Conference Call to discuss Q4FY26 Results21 May 2026 · Company Update / Analyst / Investor Meet
Ipca Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 ,inter alia, to consider and approve Standalone and Consolidated ....4 May 2026 · Board Meeting / Board Meeting
The Company has enclosing herewith certificate received from RTA under reg 74 (5) of DP Regulations for the quarter ended 31.03.2026.8 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Newspaper Notice issued by the Company regarding transfer of physical shares.2 Apr 2026 · Company Update / Newspaper Publication

Corporate actions

Purpose	Ex date	Record date	Payment date
Dividend - Rs. - 6.0000	7 Aug 2026	7 Aug 2026	—
Final Dividend - Rs. - 2.0000	5 Aug 2025	5 Aug 2025	—
Interim Dividend - Rs. - 2.0000	27 Nov 2024	27 Nov 2024	—
Final Dividend - Rs. - 2.0000	6 Aug 2024	—	—

Board meetings

5 Nov 2026 Board Meeting - Financial Results
13 Aug 2026 Board Meeting - Financial Results